AFL

Aflac Inc Price

AFL
$0
+$0(%0,00)
No data

*Data last updated: 2026-04-27 18:16 (UTC+8)

As of 2026-04-27 18:16, Aflac Inc (AFL) is priced at $0, with a total market cap of --, a P/E ratio of 0,00, and a dividend yield of %0,00. Today, the stock price fluctuated between $0 and $0. The current price is %0,00 above the day's low and %0,00 below the day's high, with a trading volume of --. Over the past 52 weeks, AFL has traded between $0 to $0, and the current price is %0,00 away from the 52-week high.

AFL Key Stats

P/E Ratio0,00
Dividend Yield (TTM)%0,00
Shares Outstanding0,00

Aflac Inc (AFL) FAQ

What's the stock price of Aflac Inc (AFL) today?

x
Aflac Inc (AFL) is currently trading at $0, with a 24h change of %0,00. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Aflac Inc (AFL)?

x

What is the price-to-earnings (P/E) ratio of Aflac Inc (AFL)? What does it indicate?

x

What is the market cap of Aflac Inc (AFL)?

x

What is the most recent quarterly earnings per share (EPS) for Aflac Inc (AFL)?

x

Should you buy or sell Aflac Inc (AFL) now?

x

What factors can affect the stock price of Aflac Inc (AFL)?

x

How to buy Aflac Inc (AFL) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts About Aflac Inc (AFL)

TechubNews

TechubNews

19 hours ago
Pulse Biosciences ($PLSE) announced the initial human feasibility study results for its nPulse cardiac catheter at the “Heart Rhythm 2026” conference. The most noteworthy part of this release is the procedural success rate and safety. At 6 months, 95 out of 95 cases were successful, achieving 100%; at 12 months, 51 out of 53 cases were successful, for a success rate of 96%. The company said that this study is of great significance as early clinical data for the treatment of atrial fibrillation (AF). The 1-year Kaplan-Meier analysis showed that the proportion of patients free from atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT) was 90%. Serious adverse events (SAE) occurred in 3 out of a total of 177 cases, for an incidence rate of 1.7%. Procedural efficiency metrics were also relatively favorable. The average device dwell time within the left atrium was 18.6±13.0 minutes, and the total procedure time was 60.2±27.7 minutes. Fluoroscopy time was 9.4±5.9 minutes, and the average number of energy applications to achieve pulmonary vein isolation (PVI) was 12.3±2.6 times. In conventional atrial fibrillation procedures, reductions in procedure time and fluoroscopy time can affect healthcare provider fatigue, patient burden, and hospital operational efficiency; therefore, these figures are sufficient to draw market attention. The result has been interpreted as an early indicator of whether Pulse Biosciences can demonstrate its technological competitiveness in the field of cardiac electrophysiology. Since it is still in the early feasibility study stage, larger-scale follow-up clinical trials and long-term follow-up data are needed. However, based solely on the data that has been published, both the “success rate” and “safety” meet expectations. If subsequent clinical trials achieve similar results, the company’s presence in the atrial fibrillation treatment device market could be strengthened. TP AI Notice: This article is summarized based on the TokenPost.ai language model. Key textual content may be omitted or may not align with actual facts.
0
0
0
0
rekt_but_vibing

rekt_but_vibing

04-08 13:17
Just looked into BlackRock's latest CEO compensation data and it's pretty wild. Larry Fink pulls in somewhere between $20-40 million annually from the company, which puts him among the highest-paid executives in the industry right now. Breaking down his 2022 comp package specifically: base salary of $1.5 million, bonus hitting $7.25 million, plus stock awards worth over $23 million. Total package came to around $32.7 million that year alone. The AFL-CIO flagged that his compensation was running 212 times what the median BlackRock employee made, which is honestly pretty standard for mega-cap CEO pay structures but still worth noting. What's more interesting is his actual stake in the company. As of early 2024, SEC filings showed he held over 414,000 BlackRock shares. At the share price back then sitting around $761, that position alone was valued north of $315 million. That's just his direct equity holdings, not counting other assets. When you factor in everything, Larry Fink's net worth hit approximately $1.1 billion as of mid-2024 according to Forbes estimates. So we're talking about someone whose wealth is deeply tied to BlackRock's performance, which probably explains why he's so focused on the company's strategic moves in crypto and ESG investing. It's a good reminder that these mega-cap CEO compensation packages are built on multiple layers - base salary, bonuses, equity awards, and then whatever else is in the fine print. The real wealth generation comes from owning a massive chunk of the company itself.
0
0
0
0